Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bogart Wealth LLC

Bogart Wealth LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 90,565 shares of the biopharmaceutical company’s stock after selling 2,218 shares during the quarter. Bogart Wealth LLC’s holdings in Gilead Sciences were worth $8,366,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new position in Gilead Sciences in the 3rd quarter valued at about $25,000. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. Valued Wealth Advisors LLC boosted its holdings in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $28,000. Finally, Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of several recent analyst reports. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday. Wolfe Research began coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price on the stock. Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday. Finally, Bank of America reiterated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a research report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $101.33.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock worth $67,684,956 over the last three months. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 2.6 %

GILD opened at $105.96 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $106.43. The stock’s 50 day moving average price is $93.38 and its 200 day moving average price is $87.24. The stock has a market cap of $132.05 billion, a P/E ratio of 1,177.33, a P/E/G ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. As a group, research analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.